New drug trial hopes to shrink Hard-to-Treat tumors

NCT ID NCT06265688

Recruiting now Disease control Sponsor: CytomX Therapeutics Source: ClinicalTrials.gov ↗

First seen Feb 28, 2026 · Last updated May 22, 2026 · Updated 11 times

Summary

This study tests a new drug called CX-2051 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety and find the best dose. About 160 adults will take part, and the drug may be given alone or with another medicine called bevacizumab.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Carolina BioOncology Institute, PLLC
RECRUITING

Huntersville, North Carolina, 28078, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Montefiore Medical Center
RECRUITING

The Bronx, New York, 10461, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
START San Antonio LLC
RECRUITING

San Antonio, Texas, 78229, United States
Sarah Cannon Research Institute at HealthONE
RECRUITING

Denver, Colorado, 80218, United States
Sarah Cannon Research Institute, LLC
RECRUITING

Nashville, Tennessee, 37203, United States

Conditions

Explore the condition pages connected to this study.

SOLID TUMOR, ADULT